Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
1643.HK Stock Summary
In the News
1643.HK Financial details
Company Rating
Buy
Market Cap
222M
Income
97.39M
Revenue
582.85M
Book val./share
0.76
Cash/share
0.47
Dividend
-
Dividend %
-
Employees
192
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
0.46
P/B
-
P/C
0.79
P/FCF
1.61
Quick Ratio
3.85
Current Ratio
5.49
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
0.12
EPS next Y
-
EPS next Q
-
EPS this Y
7.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
13.28%
Revenue last 5Y
18.16%
Revenue Q/Q
-10.84%
EPS Q/Q
-26.66%
-
-
-
-
SMA20
9.09%
SMA50
5.88%
SMA100
-10%
Inst Own
-
Inst Trans
-
ROA
18%
ROE
23%
ROC
0.29%
Gross Margin
43%
Oper. Margin
31%
Profit Margin
22%
Payout
9%
Shs Outstand
600M
Shs Float
150M
-
-
-
-
Target Price
-
52W Range
0.29-0.55
52W High
-
52W Low
-
RSI
56.17
Rel Volume
14.49
Avg Volume
145.37K
Volume
2.11M
Perf Week
-3.9%
Perf Month
19.35%
Perf Quarter
-7.5%
Perf Half Y
-7.5%
-
-
-
-
Beta
0.312
-
-
Volatility
0.02%, 0.02%
Prev Close
13.85%
Price
0.37
Change
10.45%
1643.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.29 | 0.36 | 0.51 | 0.61 | 0.67 | |
Net income per share | 0.08 | 0.08 | 0.11 | 0.14 | 0.15 | |
Operating cash flow per share | 0.13 | 0.07 | 0.07 | 0.1 | 0.21 | |
Free cash flow per share | 0.13 | 0.06 | 0.07 | -0.02 | 0.19 | |
Cash per share | 0.15 | 0.06 | 0.12 | 0.3 | 0.47 | |
Book value per share | 0.21 | 0.11 | 0.22 | 0.57 | 0.7 | |
Tangible book value per share | 0.21 | 0.11 | 0.22 | 0.57 | 0.7 | |
Share holders equity per share | 0.21 | 0.11 | 0.22 | 0.57 | 0.7 | |
Interest debt per share | 0 | 0.01 | 0.01 | 0 | 0 | |
Market cap | 663.39M | 675.03M | 636.17M | 402.27M | 291.42M | |
Enterprise value | 573.45M | 644.14M | 568.52M | 226.59M | 9.56M | |
P/E ratio | 13.75 | 14.6 | 10.01 | 4.92 | 3.32 | |
Price to sales ratio | 3.82 | 3.09 | 2.06 | 1.12 | 0.73 | |
POCF ratio | 8.6 | 16.78 | 14.88 | 6.98 | 2.32 | |
PFCF ratio | 8.62 | 17.94 | 15.07 | -31.26 | 2.55 | |
P/B Ratio | 5.36 | 9.8 | 4.72 | 1.19 | 0.69 | |
PTB ratio | 5.36 | 9.8 | 4.72 | 1.19 | 0.69 | |
EV to sales | 3.3 | 2.94 | 1.84 | 0.63 | 0.02 | |
Enterprise value over EBITDA | 8.66 | 9.64 | 6.14 | 1.94 | 0.07 | |
EV to operating cash flow | 7.44 | 16.01 | 13.3 | 3.93 | 0.08 | |
EV to free cash flow | 7.45 | 17.12 | 13.47 | -17.61 | 0.08 | |
Earnings yield | 0.07 | 0.07 | 0.1 | 0.2 | 0.3 | |
Free cash flow yield | 0.12 | 0.06 | 0.07 | -0.03 | 0.39 | |
Debt to equity | 0 | 0.07 | 0.04 | 0 | 0 | |
Debt to assets | 0 | 0.04 | 0.03 | 0 | 0 | |
Net debt to EBITDA | -1.36 | -0.46 | -0.73 | -1.5 | -2.17 | |
Current ratio | 3.2 | 1.93 | 2.54 | 5.24 | 5.49 | |
Interest coverage | 0 | 0 | 367.31 | 1.54K | 8.88K | |
Income quality | 1.2 | 0.62 | 0.47 | 0.5 | 1.01 | |
Dividend Yield | 0 | 0.15 | 0 | 0 | 0.03 | |
Payout ratio | 0 | 2.23 | 0 | 0 | 0.09 | |
Sales general and administrative to revenue | 0 | 0.06 | 0.12 | 0.06 | 0.04 | |
Research and developement to revenue | 0 | 0.04 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | -0.07 | -0.01 | -1.22 | -0.09 | |
Capex to revenue | 0 | -0.01 | 0 | -0.2 | -0.03 | |
Capex to depreciation | -0.1 | -1.69 | -0.3 | -25.88 | -2.06 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.61 | 0.45 | 0.73 | 1.33 | 1.52 | |
ROIC | 0.39 | 0.63 | 0.45 | 0.24 | 0.21 | |
Return on tangible assets | 0.28 | 0.38 | 0.3 | 0.21 | 0.18 | |
Graham Net | 0.1 | 0 | 0.03 | 0.25 | 0.37 | |
Working capital | 108.44M | 50.31M | 114.64M | 248.33M | 329.14M | |
Tangible asset value | 123.82M | 68.85M | 134.83M | 336.97M | 422.64M | |
Net current asset value | 108.44M | 50.31M | 114.44M | 248.26M | 323.89M | |
Invested capital | 0 | 0.07 | 0.04 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 13.94M | 17.59M | 27.39M | 27.85M | 34.04M | |
Average inventory | 46.28M | 39.97M | 37.45M | 46.33M | 50.1M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 26.61 | 85.05 | 57.11 | 52.01 | 62.61 | |
Days of inventory on hand | 142.6 | 124.82 | 72.15 | 105.91 | 66.2 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 13.72 | 4.29 | 6.39 | 7.02 | 5.83 | |
Inventory turnover | 2.56 | 2.92 | 5.06 | 3.45 | 5.51 | |
ROE | 0.39 | 0.67 | 0.47 | 0.24 | 0.21 | |
Capex per share | 0 | 0 | 0 | -0.12 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.38 | 0.34 | |
Net income per share | 0 | 0 | 0 | 0.07 | 0.05 | |
Operating cash flow per share | 0 | 0 | 0 | 0.12 | 0.01 | |
Free cash flow per share | 0 | 0 | 0 | 0.11 | 0 | |
Cash per share | 0 | 0 | 0 | 0.47 | 0.47 | |
Book value per share | 0 | 0 | 0 | 0.7 | 0.76 | |
Tangible book value per share | 0 | 0 | 0 | 0.7 | 0.76 | |
Share holders equity per share | 0 | 0 | 0 | 0.7 | 0.76 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 0 | 0 | 0 | 291.42M | 271.69M | |
Enterprise value | -173.56M | -175.68M | -221.64M | 9.56M | -9.72M | |
P/E ratio | 0 | 0 | 0 | 1.71 | 2.18 | |
Price to sales ratio | 0 | 0 | 0 | 1.28 | 1.33 | |
POCF ratio | 0 | 0 | 0 | 4.11 | 54.7 | |
PFCF ratio | 0 | 0 | 0 | 4.62 | -459.33 | |
P/B Ratio | 0 | 0 | 0 | 0.69 | 0.6 | |
PTB ratio | 0 | 0 | 0 | 0.69 | 0.6 | |
EV to sales | 0 | 0 | 0 | 0.04 | -0.05 | |
Enterprise value over EBITDA | 0 | 0 | 0 | 0.13 | -0.19 | |
EV to operating cash flow | 0 | 0 | 0 | 0.13 | -1.96 | |
EV to free cash flow | 0 | 0 | 0 | 0.15 | 16.43 | |
Earnings yield | 0 | 0 | 0 | 0.15 | 0.11 | |
Free cash flow yield | 0 | 0 | 0 | 0.22 | 0 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 0 | 0 | 0 | -3.88 | -5.63 | |
Current ratio | 6.08 | 5.24 | 6.77 | 5.49 | 9.95 | |
Interest coverage | 0 | 0 | 0 | 7.73K | 10.27K | |
Income quality | 0 | 0 | 0 | 1.67 | 0.16 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0.02 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0.01 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | -0.11 | -1.12 | |
Capex to revenue | 0 | 0 | 0 | -0.03 | -0.03 | |
Capex to depreciation | 0 | 0 | 0 | -2.41 | -1.57 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 0 | 0 | 1.06 | 0.94 | |
ROIC | 0 | 0 | 0 | 0.11 | 0.07 | |
Return on tangible assets | 0 | 0 | 0 | 0.08 | 0.06 | |
Graham Net | 0 | 0 | 0 | 0.37 | 0.42 | |
Working capital | 239.93M | 248.33M | 288.51M | 329.14M | 360.73M | |
Tangible asset value | 299.7M | 336.97M | 378.78M | 422.64M | 452.83M | |
Net current asset value | 239.9M | 248.26M | 288.43M | 323.89M | 354.63M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 26.36 | 10.72 | |
Days of inventory on hand | 0 | 0 | 0 | 27.87 | 25.69 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 3.41 | 8.4 | |
Inventory turnover | 0 | 0 | 0 | 3.23 | 3.5 | |
ROE | 0 | 0 | 0 | 0.1 | 0.07 | |
Capex per share | 0 | 0 | 0 | -0.01 | -0.01 |
1643.HK Frequently Asked Questions
What is Modern Chinese Medicine Group Co., Ltd. stock symbol ?
Modern Chinese Medicine Group Co., Ltd. is a CN stock and trading under the symbol 1643.HK
What is Modern Chinese Medicine Group Co., Ltd. stock quote today ?
Modern Chinese Medicine Group Co., Ltd. stock price is $0.37 today.
Is Modern Chinese Medicine Group Co., Ltd. stock public?
Yes, Modern Chinese Medicine Group Co., Ltd. is a publicly traded company.